Related Experiment Video
Updated: Jul 4, 2026
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Results of Third-Line Therapy in Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia
Wei-Ying Jen1, Elias Jabbour1, Eitan Kugler1
1Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX.
Background:
The historical results in adults with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) in second relapse treated with third-line therapy (Salvage 2) are extremely poor. Using standard chemotherapy resulted in complete response rates of 20% and a median overall survival of 2 to 3 months. This may be changing with the recent availability of novel therapeutic strategies, including targeted antibodies and engineered chimeric antigen receptor T-cell therapy, as well as more potent BCR::ABL1 tyrosine kinase inhibitors.
Study Aims:
Analyze the outcome of adults with Ph-positive ALL with different modalities in Salvage 2.
Patients And Methods:
A total of 89 adults with Ph-positive ALL in Salvage 2 treated from 1992 until 2025 were analyzed.
Results:
The complete remission (CR) rate was 58%; the 3-year survival rate was 17%. By multivariate analysis, the most significant independent favorable predictors for CR and survival were the type of therapy utilized. Among 27 patients treated since 2017, the CR rate was 89% and the 3-year survival rate 52%.
Conclusions:
Adults with Ph-positive ALL in Salvage 2 receiving third-line therapy now have reasonable outcome expectations with the newer strategies available in the past decade.
